ECA
GILD icon

Elevated Capital Advisors’s Gilead Sciences GILD Stock Holding History

Elevated Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.3K Hold
97
– – ﹤0.01% 464
2026
Q1 		$13.5K Hold
97
– – ﹤0.01% 437
2025
Q4 		$11.9K Buy
+97
New +$11.8K ﹤0.01% 440
2022
Q1 		$589K Buy
+9,906
New +$633K 0.2% 132
2021
Q3 		$665K Buy
+9,526
New +$669K 0.23% 121
2021
Q1 		$506K Buy
7,619
+1,626
+27% +$105K 0.2% 132
2020
Q4 		$349K Buy
5,993
+1,819
+44% +$110K 0.15% 145
2020
Q3 		$253K Buy
4,174
+861
+26% +$59.7K 0.12% 149
2020
Q2 		$221K Buy
+3,313
New +$254K 0.1% 150

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Elevated Capital Advisors's GILD Position: Q2 2026 in Review

Elevated Capital Advisors held its Gilead Sciences (GILD) position steady in Q2 2026 at 97 shares worth $12.3K. The position accounts for ﹤0.01% of the portfolio, ranked #464.

Elevated Capital Advisors first reported a position in GILD in Q2 2020 and has held it in 9 quarters since. The position peaked at $665K in Q3 2021. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Elevated Capital Advisors held 97 shares of Gilead Sciences worth $12.3K as of Q2 2026.
  • Elevated Capital Advisors left its Gilead Sciences share count unchanged in Q2 2026.
  • Gilead Sciences made up ﹤0.01% of Elevated Capital Advisors's portfolio in Q2 2026, its #464 holding.
  • Elevated Capital Advisors first reported a position in Gilead Sciences in Q2 2020 and has held it in 9 quarters since.
  • Elevated Capital Advisors's Gilead Sciences position peaked at $665K in Q3 2021.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Elevated Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.